Navigation Links
TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
Date:10/24/2007

AIGISRx DEB is designed to reduce the severity of capsular contracture following breast implantation via a reduction in bacterial colonization and

capsule formation

MONMOUTH JUNCTION, N.J., Oct. 24 /PRNewswire/ -- TyRx Pharma, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, announced today acceptance for presentation during the Plastic Surgery 2007 Society meeting, (October 26-31, 2007, Baltimore, MD) the paper entitled, "Prevention of Experimental Capsular Contracture in Breast Implants by an Antimicrobial-Impregnated Biodegradable Wrap". These study results demonstrate the potential of the TyRx AIGISRx DEB technology to address a significant unmet clinical need for women who have had breast augmentation.

William P. Adams, Jr., MD, Principal Investigator, Plastic Surgeon, Dallas, an international expert in breast augmentation, breast implants and capsular contracture, will present the paper during the "Hot Topics in Plastic Surgery" session, October 27 between 12-4PM. Dr. Adams was Chief of Plastic Surgery, Parkland Health and Hospital System, Dallas, and formerly Associate Professor, Department of Plastic Surgery, UT Southwestern Medical. Dr. Adams graduated B.A. Princeton University, Cum Laude, Biology and received his medical training at Vanderbilt School of Medicine. TyRx Pharma sponsored the study.

Regarding the results of the In-Vivo Efficacy Study of AIGISRx DEB, Dr. Adams remarked, "We have seen great success minimizing capsular contracture with standardized techniques and appropriate breast pocket irrigations. The study results demonstrate that this device provides superior antimicrobial protection compared to current irrigation methods with less inflammation and capsule formation. It appears that this device may greatly benefit all patients with breast implants."

Capsular Contracture, a deformation of the breast implant due to formation of fibrotic tissue following breast augmentation, affects up to 30%(1) of the approximately 290,000(2) elective breast implant procedures performed annually in the U.S. and has been the single biggest complication in aesthetic and reconstructive breast surgery since breast implants were invented 45 years ago.

"We are excited to be working with Dr, Adams in this effort," said Bill Edelman, CEO of TyRx Pharma, "The study results begin the validation of our AIGISRx DEB concept. Despite intensive therapeutic efforts spanning more than four decades, capsular contracture continues to be the most common, perplexing, and frustrating problem associated with mammary augmentation."

Although the exact etiology of capsular contracture is unknown, subclinical infection is widely believed to be the major contributor. Irrigation is a standard procedure in most clinical practices involving breast implants. "Dr. Adams is one of a handful of plastic surgeons actively studying the relationship between subclinical infection, inflammation, and capsular contracture. The data to be presented show that bacterial contamination can have a direct effect on capsular contracture," said Arikha Moses, Ph.D., CSO of TyRx Pharma.

This notice follows TyRx's August 9th announcement of Mark Citron joining TyRx as Vice President, Clinical and Regulatory Affairs.

About TyRx Pharma, Inc.

TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes combination medical products utilizing novel biomaterials technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination products. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space. For more information, please visit http://www.tyrxpharma.com.

(1) Inamed(R) Silicone-Filled Breast Implants, Directions For Use, L034-03 (C)2006 Allergan, Inc., Mentor Memorygel(TM) Silicone Gel-Filled Breast Implants, 102872-001 Rev. C Effective November 2006, Product Insert Data Sheet

(2) American Society of Plastic Surgeons, 2005 data


'/>"/>
SOURCE TyRx Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid to Buy out Bexel Pharma, US
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: